These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38493020)

  • 41. Genetic counseling referral for ovarian cancer patients: a call to action.
    Garcia C; Harrison K; Ring KL; Sullivan MW; Rauh LA; Modesitt SC
    Fam Cancer; 2019 Jul; 18(3):303-309. PubMed ID: 30993488
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical outcome in patients with primary epithelial ovarian cancer and germline BRCA1/2-mutation - real life data.
    Ataseven B; Tripon D; Schwameis R; Harter P; Rhiem K; Schneider S; Heikaus S; Baert T; Francesco AP; Heitz F; Traut A; Groeben HT; Schmutzler R; du Bois A
    Gynecol Oncol; 2021 Dec; 163(3):569-577. PubMed ID: 34565600
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Uptake and Outcomes of Neoadjuvant Chemotherapy Among US Patients With Less Common Epithelial Ovarian Carcinomas.
    Matsuo K; Matsuzaki S; Maeda M; Rau AR; Yoshihara K; Tamura R; Shimada M; Machida H; Mikami M; Klar M; Roman LD; Wright JD; Sood AK; Gershenson DM
    JAMA Netw Open; 2023 Jun; 6(6):e2318602. PubMed ID: 37326992
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Overexpression of thymic stromal lymphopoietin is correlated with poor prognosis in epithelial ovarian carcinoma.
    Xu L; Guo Y; Xu N; Chen L; Zhu J; Liu N; Zhang ZY
    Biosci Rep; 2019 May; 39(5):. PubMed ID: 31023965
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Implementation of a quality improvement project for universal genetic testing in women with ovarian cancer.
    Uyar D; Neary J; Monroe A; Nugent M; Simpson P; Geurts JL
    Gynecol Oncol; 2018 Jun; 149(3):565-569. PubMed ID: 29653687
    [TBL] [Abstract][Full Text] [Related]  

  • 46. ABCC4/MRP4 contributes to the aggressiveness of Myc-associated epithelial ovarian cancer.
    Jung M; Gao J; Cheung L; Bongers A; Somers K; Clifton M; Ramsay EE; Russell AJ; Valli E; Gifford AJ; George J; Kennedy CJ; Wakefield MJ; Topp M; Ho GY; ; Scott CL; Bowtell DD; deFazio A; Norris MD; Haber M; Henderson MJ
    Int J Cancer; 2020 Oct; 147(8):2225-2238. PubMed ID: 32277480
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Factors associated with referral and completion of genetic counseling in women with epithelial ovarian cancer.
    Alimena S; Scarpetti L; Blouch EL; Rodgers L; Shannon K; Del Carmen M; Goodman A; Growdon WB; Eisenhauer E; Sisodia RC
    Int J Gynecol Cancer; 2020 Sep; 30(9):1397-1403. PubMed ID: 32447294
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ovarian cancer: predictors of early-stage diagnosis.
    Morris CR; Sands MT; Smith LH
    Cancer Causes Control; 2010 Aug; 21(8):1203-11. PubMed ID: 20364367
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
    Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
    J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Preoperative serum 8-hydroxydeoxyguanosine is associated with chemoresistance and is a powerful prognostic factor in endometrioid-type epithelial ovarian cancer.
    Pylväs-Eerola M; Karihtala P; Puistola U
    BMC Cancer; 2015 Jul; 15():493. PubMed ID: 26134400
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Psychosocial factors associated with genetic testing status among African American women with ovarian cancer: Results from the African American Cancer Epidemiology Study.
    McBride CM; Pathak S; Johnson CE; Alberg AJ; Bandera EV; Barnholtz-Sloan JS; Bondy ML; Cote ML; Moorman PG; Peres LC; Peters ES; Schwartz AG; Terry PD; Schildkraut JM
    Cancer; 2022 Mar; 128(6):1252-1259. PubMed ID: 34882782
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Conditional disease-free survival rates and their associated determinants in patients with epithelial ovarian cancer: A 15-year retrospective cohort study.
    Ebrahimi V; Khalafi-Nezhad A; Ahmadpour F; Jowkar Z
    Cancer Rep (Hoboken); 2021 Dec; 4(6):e1416. PubMed ID: 33949809
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Application of Artificial Intelligence for Preoperative Diagnostic and Prognostic Prediction in Epithelial Ovarian Cancer Based on Blood Biomarkers.
    Kawakami E; Tabata J; Yanaihara N; Ishikawa T; Koseki K; Iida Y; Saito M; Komazaki H; Shapiro JS; Goto C; Akiyama Y; Saito R; Saito M; Takano H; Yamada K; Okamoto A
    Clin Cancer Res; 2019 May; 25(10):3006-3015. PubMed ID: 30979733
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of non-completion of intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer.
    Chambers LM; Son J; Radeva M; DeBernardo R
    J Gynecol Oncol; 2019 Nov; 30(6):e93. PubMed ID: 31576687
    [TBL] [Abstract][Full Text] [Related]  

  • 55. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Facility level variation in the utilization of neoadjuvant chemotherapy is associated with higher surgical morbidity for patients with advanced stage epithelial ovarian carcinoma.
    Nasioudis D; Latif NA; Ko EM; Cory L; Kim SH; Simpkins F; Morgan MA; Giuntoli RL
    Gynecol Oncol; 2023 Feb; 169():41-46. PubMed ID: 36502768
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical associations between ASCT2 and p‑mTOR in the pathogenesis and prognosis of epithelial ovarian cancer.
    Guo H; Xu Y; Wang F; Shen Z; Tuo X; Qian H; Wang H; Wang K
    Oncol Rep; 2018 Dec; 40(6):3725-3733. PubMed ID: 30272366
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Increasing genetic counseling referral rates through bundled interventions after ovarian cancer diagnosis.
    Swanson CL; Kumar A; Maharaj JM; Kemppainen JL; Thomas BC; Weinhold MR; Slaby KM; Mara KC; Wick MJ; Bakkum-Gamez JN
    Gynecol Oncol; 2018 Apr; 149(1):121-126. PubMed ID: 29402500
    [TBL] [Abstract][Full Text] [Related]  

  • 59.
    Kansu B; Gardner J; Price-Tate R; Murch O; Murray A
    J Obstet Gynaecol; 2021 Aug; 41(6):962-965. PubMed ID: 33228436
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genetically predicted circulating protein biomarkers and ovarian cancer risk.
    Considine DPC; Jia G; Shu X; Schildkraut JM; Pharoah PDP; Zheng W; Kar SP;
    Gynecol Oncol; 2021 Feb; 160(2):506-513. PubMed ID: 33246661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.